Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Xencor, Inc.NASDAQ: XNCR

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 75.86M shares rose 2.1% year over year, behind the +5.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.1% toward the trailing-twelve-month pace of +5.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
75.86M+0.8% QoQ
Last fiscal yearDec 2025
74.24M+14.1% YoY
LTMJun 2026
74.94M+5.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.1%——
1 year+14.1%——
3-year CAGR+7.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
74.24M USD
Year-over-year change
+14.1%
4-year CAGR
+5.3%

Weighted Avg Shares (Diluted) vs competitors

How XNCR compares with its peers on the latest reported figures

  • XNCR's LTM Jun 2026 weighted avg shares (diluted) of 74.94M shares is the 6th highest of the 11 companies compared; the peer median is 80.89M shares.
  • Its year-over-year change of +5.1% is the 6th highest of 9, against a peer median of +9.7%.
  • Over three fiscal years its annual growth of +7.6% compares with a peer median of +3.6%.
XNCR Competitors Peer median
Weighted Avg Shares (Diluted) for XNCR and competitors
Company Period LTM YoY 3-year CAGR
GMABGenmab A/SLTM Jun 2026637.25M —-1.7%
IMMPImmutep LimitedFY2025145.58M +21.2%+19.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
CGENCompugen Ltd.LTM Mar 202694.08M +4.2%+2.7%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+3.9%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
IMCRImmunocore Holdings plcLTM Mar 202650.99M -0.4%+3.3%
ADAGAdagene Inc.LTM Jun 202435.23M —+2.9%
NKTRNektar TherapeuticsLTM Jun 202623.04M +63.6%+10.6%
Peer median (excluding XNCR) 80.89M+9.7%+3.6%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue275.11M164.58M174.62M110.49M125.58M
Cost of Revenue192.51M199.56M0227.69M10.51M
Gross Profit82.6M(34.98M)174.62M(117.19M)115.06M
Gross Margin30.0%-21.3%100.0%-106.1%91.6%
Research & Development192.51M199.56M253.6M227.69M239.43M
Selling, General & Admin38.84M47.49M53.38M58.89M63.64M
Operating Expenses38.84M47.49M306.98M61.22M292.57M
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
EBITDA90.14M(45.7M)(101.96M)(186.17M)(46.98M)
EBITDA Margin32.8%-27.8%-58.4%-168.5%-37.4%
Operating Income43.77M(82.47M)(132.36M)(178.41M)(177.5M)
Operating Margin15.9%-50.1%-75.8%-161.5%-141.4%
Interest Income862K4.82M18.63M31.93M27.52M
Interest Expense13K0036.64M31.93M
Other Income / Expenses38.86M27.97M12.73M(56.52M)87.87M
Income Before Tax82.63M(54.51M)(119.63M)(234.92M)(89.42M)
Pre-Tax Margin30.0%-33.1%-68.5%-212.6%-71.2%
Income Tax Expense0673K13.66M1.62M2.5M
Net Income82.63M(55.18M)(133.13M)(232.62M)(91.92M)
Net Margin30.0%-33.5%-76.2%-210.5%-73.2%
EPS (Basic)1.42(0.93)(2.08)(3.58)(1.24)
EPS (Diluted)1.37(0.93)(2.08)(3.58)(1.24)
Weighted Avg Shares58.38M59.65M60.5M65.04M74.24M
Weighted Avg Shares (Diluted)60.5M59.65M60.5M65.04M74.24M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.